Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More Valeant Humiliation: Will The Messiness Ever End?

Executive Summary

Valeant experienced more humiliation last week, with Sequoia Fund completely exiting its position, the former CEO dumping about 5 million shares and the FDA raising suicide concerns with brodalumab, likely limiting its market potential.


Related Content

Another Black Cloud Douses Valeant's Sunlight
Valeant's Brodalumab Faces Conflicting FDA Views On Suicide Risk
Ackman Warned Valeant 'Rome Was Burning,' Begged 'Tell The Truth'
Valeant Vilified Over 'Death' Drug; Fund Managers Vexed
Valeant: Seeking Disaster Expert To Run A Hot Mess
Valeant: Another Fine Mess
AstraZeneca Unburdens Itself Of Brodalumab
Amgen dumps brodalumab; AstraZeneca losing a blockbuster?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts